InBody Co.Ltd (041830) - Total Assets
Based on the latest financial reports, InBody Co.Ltd (041830) holds total assets worth ₩318.34 Billion KRW (≈ $215.73 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 041830 book value for net asset value and shareholders' equity analysis.
InBody Co.Ltd - Total Assets Trend (2011–2024)
This chart illustrates how InBody Co.Ltd's total assets have evolved over time, based on quarterly financial data.
InBody Co.Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
InBody Co.Ltd's total assets of ₩318.34 Billion consist of 56.0% current assets and 44.0% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩31.05 Billion | 10.2% |
| Accounts Receivable | ₩22.30 Billion | 7.3% |
| Inventory | ₩37.82 Billion | 12.4% |
| Property, Plant & Equipment | ₩91.46 Billion | 29.9% |
| Intangible Assets | ₩1.85 Billion | 0.6% |
| Goodwill | ₩177.07 Million | 0.1% |
Asset Composition Trend (2011–2024)
This chart illustrates how InBody Co.Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see InBody Co.Ltd (041830) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: InBody Co.Ltd's current assets represent 56.0% of total assets in 2024, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 10.2% of total assets in 2024, down from 10.6% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 3.0% in 2011.
- Asset Diversification: The largest asset category is property, plant & equipment at 29.9% of total assets.
InBody Co.Ltd Competitors by Total Assets
Key competitors of InBody Co.Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Elbit Med Tech
TA:EMTC
|
Israel | ILA25.53 Million |
|
Value Added Technology Co. Ltd
KQ:043150
|
Korea | ₩658.61 Billion |
|
i-SENS Inc
KQ:099190
|
Korea | ₩583.47 Billion |
|
MEDIANA Co.Ltd
KQ:041920
|
Korea | ₩147.44 Billion |
|
INFINITT Healthcare Co. Ltd
KQ:071200
|
Korea | ₩229.14 Billion |
|
Sewoon Medical Co. Ltd
KQ:100700
|
Korea | ₩158.77 Billion |
|
Meta Biomed Co. Ltd
KQ:059210
|
Korea | ₩180.11 Billion |
|
MEKICS Co Ltd
KQ:058110
|
Korea | ₩55.71 Billion |
InBody Co.Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.17 | 6.69 | 7.59 |
| Quick Ratio | 4.85 | 5.31 | 6.12 |
| Cash Ratio | 0.00 | 1.64 | 0.00 |
| Working Capital | ₩147.63 Billion | ₩145.88 Billion | ₩73.24 Billion |
InBody Co.Ltd - Advanced Valuation Insights
This section examines the relationship between InBody Co.Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.24 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 11.4% |
| Total Assets | ₩305.82 Billion |
| Market Capitalization | $269.54 Million USD |
Valuation Analysis
Below Book Valuation: The market values InBody Co.Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: InBody Co.Ltd's assets grew by 11.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for InBody Co.Ltd (2011–2024)
The table below shows the annual total assets of InBody Co.Ltd from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩305.82 Billion ≈ $207.25 Million |
+11.43% |
| 2023-12-31 | ₩274.46 Billion ≈ $186.00 Million |
+13.10% |
| 2022-12-31 | ₩242.67 Billion ≈ $164.45 Million |
+19.09% |
| 2021-12-31 | ₩203.76 Billion ≈ $138.09 Million |
+22.64% |
| 2020-12-31 | ₩166.15 Billion ≈ $112.60 Million |
+7.26% |
| 2019-12-31 | ₩154.90 Billion ≈ $104.98 Million |
+17.63% |
| 2018-12-31 | ₩131.69 Billion ≈ $89.24 Million |
+17.55% |
| 2017-12-31 | ₩112.02 Billion ≈ $75.92 Million |
+15.42% |
| 2016-12-31 | ₩97.06 Billion ≈ $65.78 Million |
+17.61% |
| 2015-12-31 | ₩82.53 Billion ≈ $55.93 Million |
+30.64% |
| 2014-12-31 | ₩63.17 Billion ≈ $42.81 Million |
+17.70% |
| 2013-12-31 | ₩53.67 Billion ≈ $36.37 Million |
+11.44% |
| 2012-12-31 | ₩48.16 Billion ≈ $32.64 Million |
+9.84% |
| 2011-12-31 | ₩43.85 Billion ≈ $29.72 Million |
-- |
About InBody Co.Ltd
InBody Co.,Ltd provides body composition analysis solutions worldwide. The company offers body composition analyzers, blood pressure monitors, stadiometers, and body water analyzers, as well as InBody dial and bands. Its products are used in nephrology, liver disease, diabetes, nutrition, and rehabilitation applications. The company was formerly known as Biospace Co., Ltd. InBody Co.,Ltd was foun… Read more